

Global Influenza Medications Market Size study, by Drug Type (Antiviral [Single, Combination], Antihistamines), by Influenza Type (A, B), by Age Group, by Route of Administration (Oral, Inhaled), by Type (Branded, Generic), by Medication, by Distribution Channel and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G0D958C31460EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G0D958C31460EN

Abstracts

The Global Influenza Medications Market was valued at approximately USD 0.94 billion in 2023 and is expected to expand at a steady compound annual growth rate (CAGR) of 2.90% throughout the forecast period from 2024 to 2032. Influenza, a highly contagious respiratory illness caused by influenza viruses, continues to be a significant public health concern despite widespread vaccination efforts. The treatment landscape for influenza has evolved significantly with the introduction of advanced antiviral therapies and supportive medications designed to alleviate symptoms and reduce disease progression. Amid rising seasonal outbreaks and a growing elderly population, the demand for both branded and generic influenza medications is poised to remain strong. Pharmaceutical companies are shifting gears to diversify formulations, targeting not only treatment efficacy but also patient convenience, such as inhaled routes for faster relief.

The market is being propelled by the increasing incidence of influenza type A and B across both developed and developing nations, prompting heightened focus on quick-onset therapies and combination antivirals. Governments and healthcare institutions are scaling efforts to pre-stock flu medications in anticipation of seasonal surges, particularly in vulnerable populations such as children, the elderly, and immunocompromised individuals. Notably, the development of combination antivirals and next-generation antihistamines has widened the therapeutic scope and improved

patient outcomes. Moreover, the ongoing research around resistance mitigation, particularly against neuraminidase inhibitors, reflects a proactive industry stance toward treatment durability. However, the market faces challenges stemming from fluctuating influenza strains, dependence on accurate diagnostic tools, and occasional mismatches in vaccination strains which indirectly influence medication efficacy and demand.

As pharmaceutical innovation gathers momentum, companies are capitalizing on both generic launches and branded product lifecycle extensions to bolster their portfolios. The rising penetration of inhalable medications is gaining traction, especially among pediatric and geriatric populations, due to ease of administration and rapid symptom relief. Age-specific formulations are being introduced to improve adherence and clinical results. Moreover, the expansion of over-the-counter flu medications and antihistamine combinations in retail pharmacies is enhancing accessibility in urban as well as rural markets. Strategic distribution via e-commerce channels is also redefining how flu medications reach end-users, further stimulated by growing digital health awareness and consumer education. The convergence of medical science and technology in drug delivery is creating a dynamic ecosystem that supports the stable, long-term growth of this market.

Geographically, the market reflects diverse regional dynamics shaped by disease prevalence, healthcare infrastructure, and public health preparedness. North America remains a prominent leader, fueled by strong government procurement programs and rapid adoption of branded therapies. Europe follows closely, with regulatory support for generics and high vaccination coverage influencing seasonal medication uptake. The Asia Pacific region, however, is projected to be the fastest-growing segment due to rising healthcare expenditures, increasing urbanization, and a growing middle-class population seeking preventive care. Countries such as India, China, and Japan are experiencing heightened awareness and improved distribution networks, making them vital contributors to global market expansion. Latin America and the Middle East & Africa are gradually emerging due to strategic pharmaceutical partnerships and government-supported awareness initiatives.

Major market player included in this report are:

GlaxoSmithKline plc

F. Hoffmann-La Roche Ltd

Teva Pharmaceutical Industries Ltd

Sanofi S.A.

Cipla Ltd

Dr. Reddy's Laboratories Ltd

Sun Pharmaceutical Industries Ltd

Mylan N.V. (Viatris)

Pfizer Inc.

Novartis AG

Aurobindo Pharma Ltd

Merck & Co., Inc.

Johnson & Johnson

AstraZeneca plc

Abbott Laboratories

The detailed segments and sub-segment of the market are explained below:

By Drug Type:

Antiviral

Single

Combination

Antihistamines

By Influenza Type:

Type A

Type B

By Age Group:

Pediatric

Adult

Geriatric

By Route of Administration:

Oral

Inhaled

By Type:

Branded

Generic

By Medication:

Oseltamivir

Zanamivir

Peramivir

Baloxavir marboxil

Others

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL INFLUENZA MEDICATIONS MARKET EXECUTIVE SUMMARY

- 1.1. Global Influenza Medications Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Type
 - 1.3.2. By Influenza Type
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL INFLUENZA MEDICATIONS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Patient Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Public Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL INFLUENZA MEDICATIONS MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Increasing Seasonal Incidence of Influenza A & B
- 3.1.2. Government Pre-stocking & Procurement Initiatives
- 3.1.3. Launch of Combination Antiviral Therapies

3.2. Market Challenges

- 3.2.1. Rising Antiviral Resistance
- 3.2.2. Diagnostic Dependence and Strain Mismatch
- 3.2.3. Variable Patient Compliance

3.3. Market Opportunities

- 3.3.1. Expansion of Inhalable Medication Formats
- 3.3.2. Growth of OTC Antihistamine Combinations
- 3.3.3. Digital & E-commerce Distribution Channels

CHAPTER 4. GLOBAL INFLUENZA MEDICATIONS MARKET INDUSTRY ANALYSIS

4.1. Porter's Five Forces Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunities

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspectives

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL INFLUENZA MEDICATIONS MARKET SIZE & FORECASTS BY DRUG TYPE 2022-2032

5.1. Segment Dashboard

5.2. Global Influenza Medications Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

5.2.1. Antiviral – Single

5.2.2. Antiviral – Combination

5.2.3. Antihistamines

CHAPTER 6. GLOBAL INFLUENZA MEDICATIONS MARKET SIZE & FORECASTS BY INFLUENZA TYPE 2022-2032

6.1. Segment Dashboard

6.2. Global Influenza Medications Market: Influenza Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)

6.2.1. Type A

6.2.2. Type B

CHAPTER 7. GLOBAL INFLUENZA MEDICATIONS MARKET SIZE & FORECASTS BY REGION 2022-2032

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. Drug Type breakdown, 2022-2032

7.1.1.2. Route of Administration breakdown, 2022-2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. UK Market

7.2.2. Germany Market

7.2.3. France Market

7.2.4. Spain Market

7.2.5. Italy Market

7.2.6. Rest of Europe Market

7.3. Asia Pacific Market

7.3.1. China Market

7.3.2. India Market

7.3.3. Japan Market

7.3.4. Australia Market

7.3.5. South Korea Market

7.3.6. Rest of Asia Pacific Market

7.4. Latin America Market

- 7.4.1. Brazil Market
- 7.4.2. Mexico Market
- 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. GlaxoSmithKline plc
 - 8.1.2. F. Hoffmann-La Roche Ltd
 - 8.1.3. Teva Pharmaceutical Industries Ltd
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. GlaxoSmithKline plc
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. F. Hoffmann-La Roche Ltd
 - 8.3.3. Teva Pharmaceutical Industries Ltd
 - 8.3.4. Sanofi S.A.
 - 8.3.5. Cipla Ltd
 - 8.3.6. Dr. Reddy's Laboratories Ltd
 - 8.3.7. Sun Pharmaceutical Industries Ltd
 - 8.3.8. Mylan N.V. (Viatris)
 - 8.3.9. Pfizer Inc.
 - 8.3.10. Novartis AG
 - 8.3.11. Aurobindo Pharma Ltd
 - 8.3.12. Merck & Co., Inc.
 - 8.3.13. Johnson & Johnson
 - 8.3.14. AstraZeneca plc
 - 8.3.15. Abbott Laboratories

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Influenza Medications Market Size study, by Drug Type (Antiviral [Single, Combination], Antihistamines), by Influenza Type (A, B), by Age Group, by Route of Administration (Oral, Inhaled), by Type (Branded, Generic), by Medication, by Distribution Channel and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G0D958C31460EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0D958C31460EN.html>